The clinical impact of different assays for prostate specific

BJU International

Volumn 86, Issue 5, 2000, Pages 590-597

  Semjonow, A ^a   De Angelis, G ^a   Oberpenning, F ^a   Schmid, H P ^a   Brandt, B ^a   Hertle, L ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY DIAGNOSIS; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; REVIEW;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0033813076     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00858.x     Document Type: Review

References (49)

1. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
2. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
3. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
4. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer
5. Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma
6. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values
7. Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer
8. Multicenter tumour marker reference range study
9. Prostate-specific antigen and prostate gland volume: Correlation and clinical application
10. Correlation between prostate-specific antigen and prostate volume evaluated by transrectal ultrasonography: Usefulness in diagnosis of prostate cancer
11. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
12. The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density
13. Influence of patient age on the serum PSA concentration
14. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change
15. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
16. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin
17. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
18. Free PSA analyzed by chromatofocusing, molecular sieving and immunological methods
19. Measurement on the IMx immunoassay sytem of free and total forms of prostate specific antigen for differentiation of patients with benign prostatic hyperplasia and prostate cancer
20. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
21. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease
22. Analysis of variation in prostate-specific antigen values
23. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity
24. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen
25. Standardization of immunoassays for prostate specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design?
26. Primary care practitioners: An analysis of their perception of voiding dysfunction and prostate cancer
27. Issues in the assessment of PSA immunoassays
28. Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays
29. Comparison of a polyclonal and monoclonal immunoassay for PSA: Need for an international antigen standard
30. Variation in measurement of prostate-specific antigen: Importance of method and lot variability
31. Application of assay-specific cut-off values can improve performance of PSA tests: Results of the assay comparison study
32. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
33. Serum concentrations of prostate specific antigen and its complex with alpha1-antichymotrypsin before diagnosis of prostate cancer
34. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin
35. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model
36. Molecular cloning of human prostate specific antigen with cDNA
37. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
38. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
39. Method-to-method and lot-to-lot variation in assays for prostate-specific antigen
40. PSA standardization and quality assessment. Consensus Committee #4
41. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994
42. On the standardization of total prostate-specific antigen: An exercise with two reference preparations
43. Importance of standardisation of prostate specific antigen immunoassays in the clinical environment. Consensus Committee No 4
44. Diagnostic and prognostic application of prostate specific tissue markers: Prostate antigen (PA) and prostatic acid phosphatase (PAP)
45. Prostate-specific antigen: Quantitation in serum by immunoradiometric assay
46. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
47. Proportion of free form of PSA explains the majority of bias between the IMx (Abbott) and Tandem (Hybritech) PSA assays
48. FDA advises labs regarding off-label use of PSA assays